Profile data is unavailable for this security.
About the company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
- Revenue in USD (TTM)0.00
- Net income in USD-19.57m
- Incorporated2010
- Employees8.00
- LocationInhibikase Therapeutics Inc3350 Riverwood Parkway Se, Suite 1900ATLANTA 30339United StatesUSA
- Phone+1 (678) 392-3419
- Fax+1 (302) 655-5049
- Websitehttps://www.inhibikase.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytoDyn Inc | 0.00 | -20.53m | 140.28m | 9.00 | -- | -- | -- | -- | -0.0241 | -0.0241 | 0.00 | -0.0699 | 0.00 | -- | -- | 0.00 | -94.20 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | 1.36 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -81.67m | 142.39m | 51.00 | -- | 0.6556 | -- | -- | -1.37 | -1.37 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -29.52 | -- | -30.98 | -- | -- | -- | -- | -- | -- | -- | 0.1202 | -- | -- | -- | -22.20 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -73.10m | 143.73m | 54.00 | -- | 1.47 | -- | -- | -1.36 | -1.36 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -47.12 | -40.29 | -53.28 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| PepGen Inc | 0.00 | -87.23m | 143.75m | 64.00 | -- | 1.05 | -- | -- | -2.98 | -2.98 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -58.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Cidara Therapeutics Inc | 18.86m | -123.53m | 143.75m | 69.00 | -- | 1.24 | -- | 7.62 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 145.94m | 36.00 | -- | -- | -- | 2.96 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -32.94m | 147.32m | 22.00 | -- | 4.70 | -- | -- | -1.13 | -1.13 | 0.00 | 0.9124 | 0.00 | -- | -- | 0.00 | -91.19 | -86.31 | -107.21 | -119.59 | -- | -- | -- | -- | -- | -22.54 | 0.2384 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Sagimet Biosciences Inc | 0.00 | -37.52m | 153.25m | 10.00 | -- | 0.8979 | -- | -- | -1.29 | -1.29 | 0.00 | 5.30 | 0.00 | -- | -- | 0.00 | -27.02 | -- | -27.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -26.91m | 153.42m | 10.00 | -- | 2.08 | -- | -- | -0.2144 | -0.2144 | 0.00 | 0.5857 | 0.00 | -- | -- | 0.00 | -29.71 | -29.97 | -31.30 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -19.57m | 155.21m | 8.00 | -- | -- | -- | -- | -2.72 | -2.72 | 0.00 | -0.0711 | 0.00 | -- | -- | 0.00 | -175.81 | -66.49 | -267.87 | -85.55 | -- | -- | -- | -1,139.14 | -- | -- | -- | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Gossamer Bio Inc | 105.32m | -71.65m | 157.63m | 135.00 | -- | 2.91 | -- | 1.50 | -0.3283 | -0.3283 | 0.4595 | 0.2389 | 0.3014 | -- | -- | 780,162.90 | -20.51 | -57.43 | -23.67 | -64.38 | -- | -- | -68.03 | -- | -- | -6.84 | 0.7847 | -- | -- | -- | 21.61 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -7.54m | 158.03m | 1.00 | -- | 4.22 | -- | -- | -12.70 | -12.70 | 0.00 | 1.07 | 0.00 | -- | -- | 0.00 | -267.72 | -224.08 | -62,658.33 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -52.20m | 161.71m | 42.00 | -- | -- | -- | -- | -1.74 | -1.74 | 0.00 | -0.4749 | 0.00 | -- | -- | 0.00 | -145.85 | -- | -227.04 | -- | -- | -- | -- | -- | -- | -30.42 | -- | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Heron Therapeutics Inc | 137.74m | -27.97m | 162.74m | 126.00 | -- | -- | -- | 1.18 | -0.1841 | -0.1841 | 0.9067 | -0.2637 | 0.6122 | 0.871 | 2.11 | 1,093,151.00 | -12.43 | -53.55 | -19.65 | -71.24 | 72.19 | 52.52 | -20.30 | -170.12 | 1.74 | -- | 1.36 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Adaptimmune Therapeutics PLC - ADR | 175.04m | -44.52m | 169.20m | 449.00 | -- | 2.11 | -- | 0.9666 | -0.2126 | -0.2126 | 0.7109 | 0.3128 | 0.5701 | -- | 26.34 | 389,846.30 | -14.50 | -41.19 | -18.73 | -48.21 | -- | -- | -25.43 | -714.26 | 3.82 | -- | 0.384 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Instil Bio Inc | 0.00 | -75.17m | 170.08m | 49.00 | -- | 0.9677 | -- | -- | -11.56 | -11.56 | 0.00 | 27.02 | 0.00 | -- | -- | 0.00 | -24.53 | -- | -25.52 | -- | -- | -- | -- | -- | -- | -492.20 | 0.3179 | -- | -- | -- | 30.06 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Inhibikase Therapeutics Inc's reporting currency: US Dollar USD
45.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sands Capital Management LLCas of 21 Oct 2024 | 10.95m | 16.30% |
| Fairmount Funds Management LLCas of 09 Oct 2024 | 6.13m | 9.12% |
| Commodore Capital LPas of 09 Oct 2024 | 5.93m | 8.82% |
| Perceptive Advisors LLCas of 21 Oct 2024 | 5.93m | 8.82% |
| Armistice Capital LLCas of 30 Sep 2024 | 626.50k | 0.93% |
| Point72 Asset Management LPas of 09 Oct 2024 | 625.00k | 0.93% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 126.12k | 0.19% |
| Geode Capital Management LLCas of 30 Sep 2024 | 50.07k | 0.08% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 19.92k | 0.03% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 16.72k | 0.03% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
